Navigation Links
Drug Targets Faulty Process That Drives Cystic Fibrosis
Date:11/17/2010

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, Nov. 17 (HealthDay News) -- A new drug focused on the underlying cause of cystic fibrosis is showing promise in Phase II clinical trials, new research shows.

If eventually approved by the U.S. Food and Drug Administration, the drug known as VX-770 would mark the first treatment that gets at what goes wrong in the lungs of people with cystic fibrosis, rather than just the symptoms.

Only 4 to 5 percent of cystic fibrosis patients have the particular genetic variant that the drug is being studied to treat, according to the study.

But Robert Beall, president and CEO of the Cystic Fibrosis Foundation, said VX-770 is only the first in a new class of drugs, some of which are already in the pipeline, that may work in a similar way in people with other cystic fibrosis-linked gene variants.

"There has never been such a sense of hope and optimism in the cystic fibrosis community," Beall said. "This is the first time there's been a treatment for the basic defect in cystic fibrosis. If we can treat it early, maybe we won't have all the infections that destroy the lungs and eventually takes people's lives away."

The study appears in the Nov. 18 issue of the New England Journal of Medicine.

Cystic fibrosis is a progressive, inherited disease affecting about 30,000 U.S. children and adults. It is caused by a defect in the CF gene, which produces the CFTR (cystic fibrosis transmembrane conductance regulator) protein, which is important in the transport of salt and fluids in the cells of the lungs and digestive tract.

In healthy cells, when chloride moves out of cells, water follows, keeping the mucus around the cell hydrated.

However, in people with the faulty CFTR protein, the chloride channels don't work properly. Chloride and water in the cells of the lungs stay trapped inside the cell, causing the mucus to become thick, sticky and deh
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
2. Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building
5. FDA Targets Safety Problems With Infusion Drug Pumps
6. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
7. Combination therapy targets stubborn leukemia stem cells
8. Miami meeting on radiation therapy targets patient safety
9. Researcher targets gene regulators on link between arsenic, cancer
10. MSU targets womens health research with $2.5 million grant
11. TGen finds therapeutic targets for rare cancer in children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Targets Faulty Process That Drives Cystic Fibrosis
(Date:7/30/2014)... 2014 “United States Orthopedic Braces and Supports ... United States Orthopedic Braces and Supports market. The report provides ... and average price data (in US dollars), within market categories:, ... Ankle Braces and Supports , Spinal Braces ... , Orthotics is a specialty within the medical ...
(Date:7/30/2014)... Andover, NJ (PRWEB) July 30, 2014 Within weeks ... with excitement and promise. Each hopes this will be a time ... is reason for each to pause; it may not be as ... as 80% of students will switch their major at least once ... cost time and energy and the costs are exacerbated when switching ...
(Date:7/30/2014)... 2014 Conducting Advanced Root Cause ... Skills and Innovative Techniques to Improve the Quality ... FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... reason for 483 observations since 1997. , The ... successful CAPA program has never been more important. ...
(Date:7/30/2014)... Chesterfield, VA (PRWEB) July 30, 2014 ... will be featured in an upcoming episode of ... year via Discovery Channel. Dates and show times ... educated on Good Neighbor Community Services’ vision to ... by providing individualized and dynamic services. Through passion, ...
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... , July 30, 2014 ACCESS PHARMACEUTICALS, ... oncology supportive care, announced that its novel product for ... an article on OncLive.com titled, "Study Finds Mouth Rinse ... Dr. Steve Sonis , a leading expert in ... in the oncology community for evidence-based strategies for the ...
(Date:7/30/2014)... SAN ANTONIO , July 30, 2014 /PRNewswire/ ... technology company focused on innovating lifesaving devices and ... closed $4.5 million in Series A financing, which ... .  Proceeds from the deal will allow Bluegrass ... Inside-Out Access Catheter System, enhance manufacturing capabilities, and ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... May 26 Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... president and chief financial officer, Hill-Rom.  He will be speaking at the Jefferies ... June 9, 2010 , at 1:30 p.m. EDT .     , ... You are invited to listen to the ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... its strategic advisor as it pursues various avenues aimed at ... ANA598, in development for the treatment of hepatitis C.  Anadys ... conclusion of 12 weeks of dosing ANA598 in combination with ...
Cached Medicine Technology:Hill-Rom to Present at the Jefferies Global Life Sciences Conference 2Anadys Retains Lazard as Strategic Advisor 2Anadys Retains Lazard as Strategic Advisor 3Anadys Retains Lazard as Strategic Advisor 4Anadys Retains Lazard as Strategic Advisor 5
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... Bi-Flex bi-level system, while in BiPAP mode, ... takes to change from EPAP to IPAP. ... automatically triggers the device to cycle between ... patients breathing rhythm. Auto-Trak also compensates for ...
Functional trainer...
Medicine Products: